Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Modular Medical ( (MODD) ) just unveiled an update.
On April 16, 2026, Modular Medical announced it had regained compliance with the Nasdaq Capital Market’s minimum bid price continued listing requirement. Nasdaq notified the company on April 15, 2026, that its common stock had maintained a closing bid price above the $1.00 minimum for 10 consecutive trading days as of April 14, 2026, and that the matter is now considered closed.
The restored compliance removes an overhang regarding the company’s Nasdaq listing status and helps stabilize its capital markets position as it advances development of its next-generation insulin delivery technology. This development may reassure investors and other stakeholders about the company’s ability to maintain access to public equity markets while pursuing its growth plans in the diabetes care sector.
More about Modular Medical
Modular Medical, Inc. is a development-stage medical device company focused on innovative, patient-centric insulin delivery technology for people with diabetes. Leveraging its patented technologies, the company aims to simplify and lower the cost of advanced insulin delivery, extending high-quality glycemic control beyond experienced “superusers” to a broader patient population.
Founded by medical device veteran and microfluidics engineer Paul DiPerna, who previously founded Tandem Diabetes in 2005 and designed its t:slim insulin pump, Modular Medical is positioning itself within the diabetes care market as a provider of next-generation insulin delivery solutions. The company is listed on Nasdaq under the ticker MODD and is headquartered in San Diego, California.
Average Trading Volume: 50,566
Technical Sentiment Signal: Sell
Current Market Cap: $21.81M
For an in-depth examination of MODD stock, go to TipRanks’ Overview page.